Search Medical Condition
Please enter condition
Please choose location from dropdown

Hong Kong Island, Hong Kong Clinical Trials

A listing of Hong Kong Island, Hong Kong clinical trials actively recruiting patients volunteers.

RESULTS

Found (182) clinical trials

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

Pancreatic cancer is one of the most deadly cancers because of the predominately late diagnosis. Gemcitabine (GEM) is the standard treatment for advanced and metastatic pancreatic cancer. According to preclinical data and few early phase studies, a combined use of gemcitabine and cisplatin (CDDP) showed synergistic efficacy against pancreatic cancer. ...

Phase

0.0 miles

Learn More »

The Hong Kong CML Registry

Chronic myeloid leukaemia (CML) is a malignant disorder of the haematopoietic system characterized by the presence of the Philadelphia chromosome arising from t(9;22)(q34;q 11).The annual incidence of CML is reported to be around 1-2 cases per 100,000 population.In Hong Kong, the age-standardised incidence rate of CML has remained static in ...

Phase N/A

0.0 miles

Learn More »

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

The purpose of this study is to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)

Phase

0.0 miles

Learn More »

Pilot Study on Traditional Chinese Medicine and Food Allergy

The investigators aim to recruit 24 subjects for the present study. Subjects will be randomized into two groups, control group (n=12) and treatment group (n=12). At recruitment all subjects will be required to stop anti-allergic medicines and Chinese medicines as a wash out period for two weeks (week 1 and ...

Phase N/A

0.72 miles

Learn More »

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug

This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of ABT-494 Dose A once daily (QD) and Dose B QD versus placebo and versus adalimumab every other week (eow) in participants with moderately to severely active Psoriatic ...

Phase

1.52 miles

Learn More »

A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease (CD).

Phase

1.52 miles

Learn More »

Influence of Aspirin on Human Gut Microbiota Composition and Metabolome

Colorectal cancer (CRC) is the third most common cancer type in males and the second in females, accounting for about 693,900 deaths worldwide per year. It is commonly accepted that aspirin exerts its chemopreventive effects by inhibiting catalytic enzymes cyclooxygenase (COX) -1 and COX-2 involved in prostaglandin synthesis.This hypothetic mechanism ...

Phase N/A

1.54 miles

Learn More »

High Risk Breast Cancer Screening Program

Objectives: - To screen population with high risk for breast cancer - To promote the concept and importance of surveillance mammography - To find out the incidence of breast cancer in population who are in high risk for breast cancer - To collect blood samples for molecular analysis

Phase N/A

1.57 miles

Learn More »

Sinew Acupuncture for Knee Osteoarthritis

Objective The proposal aims to examine the efficacy and safety of sinew acupuncture for knee osteoarthritis (KOA). Hypothesis to be tested: Sinew acupuncture can reduce pain intensity, and improve knee function and health-related quality of life without significant side effects for KOA subjects compared to a sham acupuncture. Design A ...

Phase N/A

1.57 miles

Learn More »

This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients who are candidates for potentially ...

Phase

1.64 miles

Learn More »